
Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright.
The Telix Pharmaceuticals Analyst: Analyst Robert Burns initiated coverage with a Buy rating and price target of $23.